– UK, Cambridge – Healx, an AI-enabled, clinical-stage biotech company specializing in rare diseases, announced the appointment of current Non-Executve Director Dr. Jonathan Milner (Ph.D.) as the new non-executive chairman of the board of directors, effective immediately, succeeding co-founder Dr. David Brown who will remain on the board.
About Dr. Jonathan Milner
Dr. Jonathan Milner is a distinguished entrepreneur and an influential figure in the UK life sciences and biotech industry. His entrepreneurial journey includes founding Abcam, a global leader in the supply of protein research tools, which he grew into a multi-billion-dollar company before it was acquired in 2023 for nearly $6 billion. He also founded the Milner Therapeutics Institute, which bridges academia and industry to expedite drug discovery and facilitate collaborations between researchers and biopharmaceutical companies. He has a strong track record of fostering innovation in life sciences and serves on many boards, investing and contributing his expertise to numerous startups and established organizations.
Dr. Jonathan Milner said, “As Dr. Brown carves out time to embark on this new academic journey, Healx eagerly anticipates his continued scientific leadership and valuable insights while he works with the Healx team to further define the third generation of drug discovery. As the new Chairman, and speaking for the entire Healx team, we extend our heartfelt congratulations on his acceptance to Trinity College, Cambridge University as he takes another meaningful step in his illustrious career.”
About Healx
Healx is a generative AI-enabled, clinical-stage, rare disease biotech pioneering the next generation of drug discovery to bring novel, effective treatments to rare disease patients around the world. 10,000 known rare diseases affect 400 million people across the globe, but only 5% of those conditions have an approved treatment. By combining generative AI technology with deep drug discovery and development expertise, Healx can accelerate the pace, increase the scale, and improve the chance of success of rare disease treatment development to deliver global patient impact. Healx exists because every rare disease patient deserves treatment.
Healx was founded in Cambridge, UK, by Tim Guilliams, Ph.D., a biochemical engineer and tech entrepreneur, and David Brown, Ph.D., co-inventor of Viagra and former global head of drug discovery at Roche. Healx has raised approximately $110 million to date.
For more: https://healx.ai/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.